Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia

Randomized, Multicenter, Parallel, Open, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension Patient With Dyslipidemia

This study is to Compare the Efficacy and Safety of Rosuvastatin/Amlodipine Combination Therapy Versus Atorvastatin/Amlodipine Combination Therapy in Hypertension patient with Dyslipidemia

Inclusion Criteria:

• Both man and woman who is over 19 years old
• Patient with dyslipidemia and hypertension
• Written informed consent

Exclusion Criteria:

• Triglyceride ≥ 400 mg/dL at screening
• Hypertensive patients who need antihypertensive medication except Amlodipine, β-blockers, RAS inhibitors
• sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg
• A history of rhabdomyolysis, myopathy
• Patient with hypersensitivity to Statin or Amlodipine
• Patients undergoing eGFR <30 mL/min/1.73 m2 (MDRD) at screening
• AST(Aspartate Aminotransferase) or ALT(Alanine Aminotransferase) level ≥ 3x ULN (upper limit of normal range) or active liver disease
• Creatine kinase (CK) level ≥ 5x ULN (upper limit of normal range)
• Contraindications stated in the Label of Rosuampin or Caduet
• Those participating in other clinical trials for investigational products at screening
• Patients deemed to be ineligible to participate in the trial by investigator